AR9281: Phase Ib data

Top-line data from a 7-day, double-blind, placebo-controlled, U.S. Phase Ib trial in 24 healthy volunteers showed that up to 1,200 mg/day of oral AR9281 was well tolerated with no observed dose-relate...